Profile data is unavailable for this security.
About the company
Lavipharm SA is a Greek commercial and industrial enterprise engaged in the development, manufacture, marketing and distribution of pharmaceutical, cosmetic and over-the-counter (OTC) products. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. It is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.
- Revenue in EUR (TTM)50.93m
- Net income in EUR2.00m
- Incorporated1975
- Employees189.00
- LocationLavipharm SAAgias Marinas Street, PeaniaPO Box 59ATHINA 190 02GreeceGRC
- Phone+30 2 106691000
- Fax+30 2 106642310
- Websitehttps://www.lavipharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transgene SA | 7.63m | -22.33m | 131.81m | 158.00 | -- | 8.37 | -- | 17.27 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
| Heidelberg Pharma AG | 9.05m | -18.28m | 135.15m | 98.00 | -- | 3.00 | -- | 14.93 | -0.3957 | -0.3957 | 0.196 | 0.968 | 0.1222 | 0.2187 | 11.87 | 95,273.69 | -24.68 | -43.91 | -33.18 | -64.34 | 79.75 | 52.13 | -201.94 | -206.24 | 2.22 | -- | 0.104 | -- | -46.75 | 21.87 | -3.27 | -- | -0.8341 | -- |
| Molecular Partners AG | 6.95m | -60.47m | 139.08m | 168.00 | -- | 0.7157 | -- | 20.02 | -1.78 | -1.78 | 0.2043 | 5.13 | -- | -- | -- | 40,035.71 | -- | -11.83 | -- | -14.69 | -- | 99.28 | -870.22 | -45.30 | -- | -- | 0.0195 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
| Futura Medical PLC | 3.65m | -7.67m | 139.35m | 12.00 | -- | 21.60 | -- | 38.16 | -0.0219 | -0.0219 | 0.0105 | 0.0182 | 0.3391 | -- | 5.09 | 258,414.20 | -71.22 | -79.25 | -127.75 | -127.22 | 57.22 | -- | -210.03 | -914.37 | 1.47 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Eurobio Scientific SA | 130.00m | 4.84m | 150.66m | 137.00 | 34.07 | 0.9174 | 8.38 | 1.16 | 0.4315 | 0.4315 | 11.59 | 16.02 | 0.4018 | 3.19 | 4.31 | 948,927.00 | 1.49 | 16.91 | 1.80 | 21.53 | 47.11 | 50.95 | 3.72 | 23.34 | 2.32 | 4.03 | 0.3666 | 0.00 | -14.81 | 20.80 | -80.61 | -- | 20.02 | -- |
| Lavipharm SA | 50.93m | 2.00m | 152.26m | 189.00 | 76.22 | 3.56 | 17.83 | 2.99 | 0.0119 | 0.0112 | 0.3034 | 0.2546 | 0.4449 | 2.21 | 2.62 | 269,465.60 | 1.74 | 3.47 | 2.71 | 5.58 | 45.55 | 42.92 | 3.92 | 5.76 | 0.8608 | 3.06 | 0.4308 | -- | 10.70 | 8.38 | 139.57 | 9.85 | 31.88 | -- |
| Photocure ASA | 44.33m | 417.05k | 154.61m | 102.00 | 375.61 | 3.70 | 53.96 | 3.49 | 0.1755 | 0.1755 | 19.02 | 17.82 | 0.7215 | 0.9144 | 7.93 | 5,024,010.00 | 0.6789 | -3.06 | 0.7682 | -3.54 | 94.65 | 93.64 | 0.941 | -5.15 | 4.33 | -- | 0.00 | -- | 27.35 | 22.50 | 101.36 | -- | 49.83 | -- |
| Devyser Diagnostics AB | 15.85m | -4.03m | 155.88m | 124.00 | -- | 4.74 | -- | 9.83 | -2.83 | -2.83 | 11.13 | 23.00 | 0.3671 | 1.56 | 5.11 | 1,529,661.00 | -9.33 | -8.97 | -10.65 | -10.15 | 84.76 | 80.14 | -25.43 | -23.91 | 4.34 | -- | 0.1543 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
| Ose Immunotherapeutics SA | 2.23m | -23.00m | 162.82m | 62.00 | -- | 7.03 | -- | 73.11 | -1.18 | -1.18 | 0.1166 | 1.06 | 0.0256 | -- | 3.22 | -- | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -97.81 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
| Nanoform Finland Oyj | 2.42m | -23.23m | 169.69m | 166.00 | -- | 2.57 | -- | 70.02 | -0.2974 | -0.2974 | 0.031 | 0.774 | 0.0287 | 100.58 | 4.29 | 14,687.82 | -27.47 | -27.13 | -30.12 | -29.48 | -576.50 | -604.26 | -958.65 | -1,023.70 | 6.60 | -- | 0.091 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Inventiva SA | 17.48m | -110.43m | 172.13m | 112.00 | -- | -- | -- | 9.85 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Cellectis SA | 11.16m | -72.16m | 173.08m | 235.00 | -- | 2.08 | -- | 15.50 | -1.22 | -1.03 | 0.1637 | 1.16 | 0.04 | -- | 1.41 | 47,502.20 | -27.82 | -24.08 | -42.40 | -30.69 | -- | -64.64 | -694.72 | -308.24 | -- | -- | 0.552 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
| Avacta Group Plc | 27.38m | -29.38m | 173.38m | 154.00 | -- | -- | -- | 6.33 | -0.0914 | -0.0914 | 0.0853 | -- | -- | -- | -- | 150,954.50 | -- | -- | -- | -- | 48.37 | -- | -107.31 | -- | -- | -0.575 | -- | -- | 140.83 | -- | 32.54 | -- | -- | -- |
| Aelis Farma SA | 9.05m | -5.08m | 173.68m | 26.00 | -- | 13.16 | -- | 19.18 | -0.3907 | -0.3907 | 0.7019 | 0.9957 | 0.2765 | -- | 2.41 | 348,230.80 | -15.51 | -24.53 | -25.59 | -40.55 | -- | -- | -56.09 | -109.62 | 2.47 | -- | 0.1547 | -- | 137.70 | -- | 64.46 | -- | 37.35 | -- |
Data as of Jun 07 2024. Currency figures normalised to Lavipharm SA's reporting currency: Euro EUR
0.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Eurobank Asset Management M.F.M.C. SAas of 31 Dec 2023 | 570.00k | 0.30% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 148.16k | 0.08% |
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
